Rank ligand inhibition - a potential chemoprevention strategy for women at high genetic risk of breast cancer HHSN2612015000181 to: HHSN26100008 PP: 9/17/18 to 3/16/2021
Ended Awarded Last action
- Contract number
- 75N91018F00009
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $849,016
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $849,016.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $205,630 | |
| Original award | $643,386 |
About this award
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price delivery order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $849,016 contract, which runs from September 17, 2018 to December 16, 2022, supports the "Rank Ligand Inhibition - A Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer" project under the Preclinical Prevention Cancer Program. This contract was not set aside for any specific business type. The University of Texas MD Anderson Cancer Center is a comprehensive cancer treatment and research center that conducts a wide range of cancer-related research, including preclinical studies, clinical trials, and public health initiatives, supported by federal funding from agencies such as the National Institutes of Health, Department of Defense, and Centers for Disease Control and Prevention.
Quick answers
Who was awarded contract 75N91018F00009?
75N91018F00009 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 17, 2018.
How much is contract 75N91018F00009 worth?
The government has obligated $849,016 on 75N91018F00009.
Is contract 75N91018F00009 an order under another contract?
Yes. 75N91018F00009 is a delivery order under HHSN261201500018I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract 75N91018F00009 competed?
The extent of competition for 75N91018F00009 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award